Kornimate/medical-research-clean huggingface dataset:
investigation on the surgical treatment effect of periprosthetic femur fracture after hip arthroplasty

Conditions: Periprosthetic Fractures

Summary: to investigate the surgical treatment effect of periprosthetic femur fracture after hip arthroplasty

in the study，155 patients from multiple center with periprosthetic femur fracture after hip arthroplasty are planned to be recruited. all the patients are treated surgically according to vancouver classification，and their fracture union，pain in fracture site and lower extremity length are evaluated at 6 months and 1 year postoperatively．also harris scores are used to assess hip function at the 2 time points.

Eligibility criteria:
inclusion criteria: patients with periprosthetic femur fracture after hip arthroplasty exclusion criteria: severe complications after surgery

Keywords: periprosthetic fractures arthroplasty surgical procedures
dexamethasone (sterodex) versus loteprendol (lotemax) eye drops following strabismus surgery

Conditions: Ophthalmology

Summary: the purpose of this study is to compare the efficacy and side effects of topical loteprendol etabonate 0.5% (lotemax) versus dexamethasone 0.1% (sterodex) following strabismus surgery.

this is a randomized prospective study that will involve 100 patients (males and females) undergoing strabismus surgery. all patients will be randomly assigned to receive one of the study drugs (loteprendol etabonate 0.5% (lotemax) drops or dexamethasone 0.1% (sterodex) drops) after undergoing strabismus surgery. in addition to the study drug all patients (in both groups) will receive topical ofloxacin 0.3% (oflox) eye drops. all patients will undergo a complete ophthalmological evaluation before surgery including orthoptic assessment of their strabismus and measurement of intraocular pressure (iop). topical treatment with the study drug and topical ofloxacin 0.3% (oflox) eye drops will begin on the evening of the surgery, following a schedule that will be the same for both groups: 4 times daily during the first week, 3 times daily for the second group, twice daily for the third week, and as needed for the fourth week. all patients will be examined at 1 day, 1 week, 2 weeks and 4 weeks after surgery by a masked investigator (not the strabismus surgeon). the parameters to be checked will include: 1. patient pain and discomfort 2. conjunctival chemosis 3. conjunctival hyperaemia 4. conjunctival discharge 5. conjunctival gap 6. intraocular pressure (iop) 7. number of pain control medications taken

Eligibility criteria:
inclusion criteria: * patients undergoing recession strabismus surgery through a fornix approach of one of the horizontal recti muscles (either medial rectus or lateral rectus) or of the inferior oblique muscle * must be able to comply with topical treatment * must be able to comply with post-operative appointment schedule. exclusion criteria: * previous ocular surgery (including previous strabismus surgery) * ocular pathology * family history of glaucoma * personal history of allergic drug reaction or allergic conjunctivitis * more than one muscle operated on * adjustable sutures technique * patients in whom it is impossible to measure iop before surgery
a dose-response trial using rfsh fe 999049 in women undergoing ivf/icsi treatment

Conditions: Infertility

Summary: this trial investigates the effects of several doses of fe 999049 in women undergoing ivf/icsi (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.


Eligibility criteria:
inclusion criteria: * women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage i/ii or with partners diagnosed with male factor infertility * women eligible for ivf (in-vitro fertilisation) and/or icsi (intracytoplasmic sperm injection) treatment * women aged 18-37 years * women with body mass index (bmi) of 18.5-32.0 kg/m2 exclusion criteria: * women with polycystic ovary syndrome (pcos) associated with anovulation, endometriosis stage iii/iv * women with history of recurrent miscarriage * women with contraindications to controlled ovarian stimulation with gonadotropins * women with three or more controlled ovarian stimulation cycles
efficacy of metacognitive training single modules: jumping to conclusions and to empathize...

Conditions: Schizophrenia; Psychotic Disorders

Summary: the purpose of this study is to determine whether modules of metacognitive training: jumping to conclusions and to empathize... are effective in the treatment of patients with schizophrenia. also it was investigated whether these modules have specific impact on cognitive biases severity.

investigators employ randomized controlled trial design. patients in ward were recruited for the study in three waves. in each wave patients were assessed pre-intervention, then randomly allocated in one of three groups: with modules of metacognitive training or control group. then patients were assessed post-intervention.

Eligibility criteria:
inclusion criteria: * diagnosis of psychotic disorders * informed consent exclusion criteria: * neurological disorders

Keywords: schizophrenia randomized controlled trial metacognitive training single sessions
assessment of probiotics on inflammation and metabolism in type 2 diabetes.

Conditions: Type 2 Diabetes

Summary: this clinical study aims to explore the effects of probiotics on inflammatory and metabolic indicators in patients with type 2 diabetes. by assessing the potential of probiotics to modify these markers, the study seeks to identify an economical and effective strategy for the prevention and treatment of type 2 diabetes.


Eligibility criteria:
inclusion criteria: 1. signed an informed consent form before the study and has a thorough understanding of the content, process, and possible adverse reactions of the study; 2. age 18 (inclusive) and above, gender not limited; 3. diagnosed with type 2 diabetes mellitus; 4. not diagnosed with cardiovascular, kidney, or any other diabetic complications. exclusion criteria: 1. age over 75 years old; 2. use of exogenous insulin or patients with cardiovascular disease and other complications; 3. patients who are currently using α-glucosidase inhibitors; 4. patients who have a habit of taking probiotics or are currently taking probiotics; 5. pregnant or lactating women; 6. subjects deemed unsuitable for participation in this clinical study by the investigators due to other reasons.
self-assembling peptide with sodium fluoride in treating white spot lesionss in primary teeth

Conditions: White Spot Lesion

Summary: regenerative medicine-based approaches for caries treatment focus on biomimetic remineralization of initial carious lesions as a minimally invasive therapy using self-assembling peptide p11-4 (curodonttm repair) which enhances remineralization of white spot lesions (wsls). the study aimed to assess clinically the effect of self assembling peptide p11-4 (curodonttm repair) + fluoride varnish (duraflor) versus a 5% fluoride varnish (duraflor) on remineralization of enamel white spot lesions in primary teeth.


Eligibility criteria:
inclusion criteria: * children with high caries risk with the presence of at least one visible active wsl in primary teeth with icdas ii score of 1, 2 or 3 exclusion criteria: * children with systemic diseases * teeth with cavitated lesion involving dentin and enamel defects
distribution of the homologous recombination-related (hrr) genesmutationsand hrd in breast cancer

Conditions: Breast Cancer; HER2-low Breast Cancer

Summary: this was a cross-sectional and an observational study, investigator-initiated study in her2-low breast cancer patients. approximately 335 subjects will be enrolled in this study to examine the distribution and features of hrd (homologous recombination deficiency)/hrr (homologous recombination repair). in this study, investigators plan to clarify the frequency of hrr/hrd in chinese patients with her2-low breast cancer. in addition, it is planned to investigate any association between invasive disease-free survival (idfs) / overall survival (os) and hrd/hrr in her2-low breast cancer patients.


Eligibility criteria:
inclusion criteria: 1. female patients who have pathologically documented breast cancer that: has a history of her2-low expression, defined as ihc 2+/ish- or ihc 1+ (ish- or untested) with a validated assay asco/cap guidelines in the metastatic setting 2. femalepatients must be at least 18 years of age 3. ecog performance status of 0 or 1 4. patients with operable primary breast cancer who underwent radical surgery and no patients received preoperative neoadjuvant therapy. 5. no distant metastasis occurred 6. patient must have adequate tumor andbloodsample for biomarker assessment exclusion criteria: 1. recurrent or advanced metastatic breast cancer 2. bilateral breast cancer (including multifocal breast cancer. all histological lesions were her2 1+ or 2+, not detected by fish amplification and hr positive according to asco guidelines) 3. other malignant tumors within 5?years 4. clinical diagnosis and treatment information is incomplete

Keywords: homologous recombination-related homologous recombination deficiency
characterizing the inflammation around dental implants: bacterial infection, hypersensitivity or both?

Conditions: Dental Implant Failed; Implant Complication; Implant Site Infection; Implant Site Reaction

Summary: the use of titanium dental implants has become a common modern treatment to restore teeth. although the success rate of dental implants is high, inflammation around the dental implant still occurs. the current study will investigate if the inflammation around the implant is due to bacterial infection, hypersensitivity or both.

the objective of the study is to: 1. establish the levels of cytokines in peri-implant crevicular fluid and test the levels of cytokines associated with hypersensitivity (type 2: interleukin-4 \[il-4\], interleukin-5 \[il-5\], and interleukin-13 \[il-13\]) and bacterial infection (type 1 and 3: interleukin-1 alpha \[il-1α\], interleukin-2 \[il-2\], interleukin-6 \[il-6\], interleukin-8 \[il-8\], interleukin-10 \[il-10\], interleukin-12 \[il-12\], interleukin-17 \[il-17\], granulocyte-macrophage colony-stimulating factor \[gm-csf\], interferon-gamma \[ifn-γ\], tumor necrosis factor-alpha \[tnf-α\]) between healthy implants and inflamed implants (mucositis and peri-implantitis). 2. compare the levels of matrix metalloproteinases (mmps: mmp-1, mmp-2, and mmp-9) and receptor activator of nuclear factor kappa-β ligand (rankl) associated with tissue destruction and bone loss between healthy and inflamed implants.

Eligibility criteria:
inclusion criteria: * received at least one functional implant (implant restored with a prothesis); * did not receive peri-implant mucositis and peri-implantitis treatment in the past three months. exclusion criteria: * dental records with incomplete information; * individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease; * pregnant women; * individuals undergoing orthodontic therapy and those who have oral piercing. * history of diseases that modify or suppress the immune and inflammatory response, including rheumatoid arthritis, diabetes, lupus, and inflammatory bowel disease and metastatic cancer; * taking medications that cause antiresorptive osteonecrosis of the jaw (including any dose of intravenous bisphosphonates, oral bisphosphonate intake for more than three years, receptor activator of nuclear factor kappa-b ligand inhibitors, or antiangiogenic medications); * taking medications known to induce gingival hyperplasia including anticonvulsants, immunosuppressants, or calcium channel blockers; * taking steroid medications, systemic or local antibiotics in the last three months (as this may affect the interleukins activity); * received radiation therapy to the head and neck or chemotherapy; * received treatment to manage an inflamed implant, including management of peri-implantitis and peri-implant mucositis in the last three months.

Keywords: dental implant peri-implant inflammation inflammatory mediators bacterial infection hypersensitivity peri-implantitis
a study of complex ventral hernia repair utilizing the xenmatrix™ surgical graft with component separation

Conditions: Hernia

Summary: this will be an observational study designed to collect early, short- and long-term clinical outcomes of the xenmatrix™ surgical graft for complex ventral hernia repair. subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.


Eligibility criteria:
inclusion criteria: * be able to undergo study procedures. * have signed an informed consent form (icf). * be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator. * requires a component separation repair with the use of a biological graft. exclusion criteria: * subject is participating in another device or drug study. * subject has a life expectancy less than 4 years at the time of enrollment. * any condition in the opinion of the investigator that would preclude the use of the xenmatrix™ surgical graft, or preclude the subject from completing the follow-up requirements. * any subject with a defect the surgeon feels he/she cannot fully close. * subjects with a bmi \> 50. * subjects with connective tissue disorders. * subjects with a history of cirrhosis. * subjects with renal failure requiring dialysis. * subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study. * transplant recipients. * subjects taking corticosteroids for \>6 months (pre or post surgery). * any bowel leak or infection that would preclude the use of the xenmatrix™ surgical graft in the opinion of the investigator. * the subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.
vitamin c level effect in orthognathic surgery

Conditions: Maxillofacial Abnormalities; Maxillofacial Injuries; Maxillofacial Trauma

Summary: comparing the pre and post-operative blood plasma levels of vitamin c according to oxidative stress and investigate the correlation between post-operative analgesia requirement and vitamin c levels following orthognathic surgery.

vitamin c (ascorbic acid) is a water-soluble vitamin that has many functions include antioxidant, neuroprotective, neuromodulator and co-factor for various enzymes or chemical reactions. primarily ascorbic acid is the most potent non-enzymatic antioxidant agent in an extracellular fluid which is crucial for defense against oxidative stress. recent clinical studies have shown that trauma or surgery may lead to oxidative stress and plasma vitamin c level decreases due to body demand that most likely caused by oxidative stress. pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. one of the major purposes in the management of post-operative pain is to minimize the dose of medications to reduce side effects while providing adequate analgesia. in orthopedic surgery and management of postherpetic neuralgia oral vitamin c supplementation significantly reduced pain. however, the decrease in vitamin c concentration,the effects on antinociception and postoperative pain are not fully understood. in this study, investigators aimed to compare pre and post-operative blood plasma levels of vitamin c after orthognathic surgery and investigate a correlation between post-operative analgesia requirement and vitamin c levels without vitamin c administration.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) classification i-ii * scheduled for orthognatic surgery under general anesthesia exclusion criteria: * history of bleeding diathesis, * receiving anticoagulant treatment, * known local anesthetics and opioid allergy, * infection of the skin at the site of the needle puncture, * pregnancy or lactation, * patients who do not accept the procedure
pan-intestinal capsule endoscopy versus colonoscopy in iron deficiency anemia or overt gi bleeding

Conditions: Iron Deficiency Anemia; GastroIntestinal Bleeding

Summary: the authors hypothesize that in patients with iron deficiency anemia or gastrointestinal bleeding, pan-intestinal capsule endoscopy is a safe and well tolerated procedure that may improve diagnostic yield comparatively to the current standard invasive colonoscopy.

patients presenting with iron deficiency anemia (ida) or overt gi bleeding are often submitted to conventional upper gi endoscopy and colonoscopy, followed by small bowel capsule endoscopy if diagnosis remains elusive. recently, however, the possibility of performing pan-intestinal endoscopy using a video capsule that evaluates both the small bowel and the colon in a single non-invasive examination, opens new perspectives for the management of those conditions, particularly when the initial upper gi endoscopy has been non-diagnostic. the authors hypothesize that performing early pan-intestinal capsule endoscopy strategy may allow, in a safe and well tolerated manner, to identify which patients would benefit of further interventions, such as colonoscopy or invasive enteroscopy, guided by findings pre-identified at capsule examination. the study aims to evaluate whether pan-intestinal capsule endoscopy is superior to the current standard strategy of conventional colonoscopy after non-diagnostic upper endoscopy in patients with ida or overt gi bleeding, regarding diagnostic yield, safety and tolerability.

Eligibility criteria:
inclusion criteria: * patients from external consultation, hospital ward or urgency department, with suspected gi bleeding presenting in the occult form as ida (hb \<12.0 g/dl in female gender or \<13.0 g/dl in male gender) and/or overt gi bleeding presenting as melaena and/or haematochezia, and with prior non-diagnostic upper gi endoscopy (esophagogastroduodenoscopy, egd) exclusion criteria: 1. lack of informed consent 2. suspected lesions at index egd that could justify the anemia or digestive bleeding 3. known history of gastroparesis or bowel dysmotility 4. known or suspected intestinal stricture 5. female patients with potential gynaecological source of bleeding causative of the clinical condition 6. patients with severe malnutrition 7. patients unable to walk at least for short periods and/or with neurological and/or psychiatric condition potentially favouring protocol deviations 8. allergy or contra-indications to any of the drugs or products used in the study 9. pregnancy or breastfeeding

Keywords: iron deficiency anemia gastrointestinal bleeding pan-intestinal capsule endoscopy
eye injections of bevacizumab for lowering risk of scar tissue in the retina and repeated retinal detachment.

Conditions: Retinal Detachment; Vitreoretinopathy Proliferative

Summary: the purpose of this study is to examine the effects of a drug called bevacizumab (avastin) on the rates of recurrent retinal detachment and scar tissue formation.

proliferative vitreoretinopathy (pvr) remains the most significant obstacle to successful retinal detachment (rd) repair, accounting for up to 75% of all primary surgical failures. characterized by the proliferation of cells on the preretinal or subretinal surface, pvr ultimately leads to contraction, foreshortening, and ultimately recurrent detachment of the retina. several pvr risk factors have been identified, including pre-existing uveitis, large retinal tears, multiple retinal breaks, detachments involving greater than two quadrants of the retina, vitreous hemorrhage, and choroidal detachment. given the absence of a proven medical therapy for pvr and prior studies establishing vegf as a potential therapeutic target, further clinical evaluation is warranted. herein, we report outcomes of a prospective, non-randomized, historical-control pilot study evaluating the effect of serial intrasilicone oil bevacizumab injections on outcomes of pvr-related rd repair.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * undergoing pars plana vitrectomy with or without scleral buckling for recurrent rd due to pvr with planned silicone oil instillation. exclusion criteria: * prior anti-vegf (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery. * traction retinal detachment due to proliferative diabetic retinopathy. * inability to flatten retina completely intraoperatively * known allergy or contraindication to intravitreal bevacizumab

Keywords: pvr rd proliferative vitreoretinopathy retinal detachment detachment
flx475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Conditions: Gastric Cancer

Summary: this clinical study is a phase 2, open-label study to assess the efficacy, safety profile of flx475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. this study is designed to assess the potential anti-tumor activity when administered at the 100mg qd of flx475 with pembrolizumab and will be conducted (2) cohorts as detailed below. * cohort 1: ebv negative / cpi naïve gastric cancer subjects who have progressed on at least 2 prior systemic treatments for advanced or metastatic gastric cancer * cohort 2: ebv positive / cpi naïve gastric cancer subjects who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer approximately 90 subjects may be enrolled across two cohorts to examine the safety and efficacy.


Eligibility criteria:
inclusion criteria: * all patients must have histologically or cytologically confirmed, advanced, relapsed or metastatic gastric or gastroesophageal junction adenocarcinoma * patient must have one of the following diagnoses to be eligible for enrollment into cohorts: * cohort 1: checkpoint inhibitor naïve epstein-barr virus negative (ebv-) gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer * cohort 2: checkpoint inhibitor naïve epstein-barr virus positive (ebv+) gastric cancer patient (as determined by standard methods, e.g. eber ish or lmp-1 ihc) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer * eastern cooperative oncology group (ecog) performance status 0-1 * patient must have at least one measurable lesion at baseline by computed tomography(ct) or magnetic resonance imaging (mri) * tumor available for biopsy exclusion criteria: * prior therapy with an anti-pd-1, anti-pd-l1, or anti-pd-l2 agent or an agent directed to another stimulatory or co-inhibitory t-cell receptor (e.g., ctla-4, ox-40, cd137), any history of discontinuing from that treatment due to grade 3 or higher immune-related adverse event (irae) * patient with msi-h status * active autoimmune disease or serious autoimmune disease within past 2 years requiring systemic therapy * history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, (non-infectious) pneumonitis that required steroids, or clinical symptoms of active pneumonitis * significant cardiovascular disease. new york heart association (nyha) class 3 or 4 congestive heart failure, or chronic grade 3 hypertension. * significant screening electrocardiogram (ecg) abnormalities * has had an allogenic tissue/solid organ transplant